Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. - Wikidata - wikimedia - TriplyDB

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

http://www.wikidata.org/entity/Q33952538

about

Challenges and opportunities for the implementation of virological testing in resource-limited settings Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa Gender perspective of risk factors associated with disclosure of HIV status, a cross-sectional study in Soweto, South Africa Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015.Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.Changes in second-line regimen durability and continuity of care in relation to national ART guideline changes in South Africa Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settings.HIV prevention counseling intervention delivered during routine clinical care reduces HIV risk behavior in HIV-infected South Africans receiving antiretroviral therapy: the Izindlela Zokuphila/Options for Health randomized trial Community viral load and CD4 count distribution among people living with HIV in a South African Township: implications for treatment as prevention Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study.Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting Association of first-line and second-line antiretroviral therapy adherence.Predictors of raised viral load during antiretroviral therapy in patients with and without prior antiretroviral use: a cross-sectional study.Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa Comparison of pharmacy-based measures of adherence to antiretroviral therapy as predictors of virological failure Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.Outcome of patients on second line antiretroviral therapy under programmatic condition in India Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.Correlates of mobile phone use in HIV care: Results from a cross-sectional study in South Africa.High prevalence of PI resistance in patients failing second-line ART in Vietnam.The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system.Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting.

P2860

Q27026923-21B37963-9DE1-47F6-B814-246ED14D5A4E Q28477379-FBEF5C51-8B2D-47CF-B4BC-5249A1278490 Q28481468-CC49C494-7865-4E0F-A617-E9AAEA18813B Q28535483-26D7335E-E2EF-4383-8E38-AA3AA291337F Q28538018-8888B93F-5E19-4933-8C60-87EC9453781D Q33634625-14F7ABDB-7889-4626-9FD6-9C32C2DB12F2 Q33712438-EFFEB587-3AC2-45AB-94AB-E37C7A13B116 Q33777513-A3A3C77F-00AE-4817-A598-F239D6D1E95B Q33814942-F9C18A82-D186-43C1-A470-25A9B6DA22B0 Q33901360-FA621AF2-D27B-4557-A9B6-D5CA2F6ECDA3 Q34222186-3A3CF527-F8AB-4455-BCE2-8842EE1AC96C Q34292437-9F6CD8AC-34BD-4DDE-AED2-F5CBEA4D6178 Q34303603-ED59B55D-254E-44B5-B4AA-35917ED4F80B Q34325958-DE4CE83D-E37F-48DE-9A80-EB8324659C46 Q34498574-D9D48203-4444-44C6-92A0-46ADEB865C90 Q34519553-ABC2F304-40C5-4C36-AE74-8FF7CAD6DEB5 Q34625910-98870B27-4ECD-4E51-9041-24524AC0AABB Q34706948-1759965E-25F6-4D34-9024-380FCCABB786 Q34734833-223AB78A-55AC-4234-BB8F-3E7E2E83A0B5 Q34778123-5E060392-825C-406E-A5B8-F3D84418084E Q34801978-94E5E468-6926-4789-A0AF-7978D742A4A3 Q34963950-35606F7D-0505-48C0-B011-1632D71FFE10 Q34998736-E12B58DB-C58A-40AE-A90C-F5AF62571870 Q35105844-7F982AD2-BA52-4205-A441-0F9522336FD9 Q35217629-2189915B-4C50-4D69-9E38-C518600866BD Q35370804-87672BC7-6552-4AFC-BBCD-8622E8E2DB0B Q35403205-08B11EE6-B383-4D38-8B3B-DA4F833199A1 Q35760170-9A9CE991-6C80-4A2F-B105-3817F6E2CFDD Q35842413-FB76E22F-3B32-4C1A-94B4-C70AA09CAE37 Q36109276-54E8AE1B-AD56-4775-B37A-65295A24424A Q36179320-1A2908F6-A526-4351-B70F-B413B04E81F6 Q36226907-7062B3CF-0E85-4C7D-A2D5-8065D9CD9D28 Q36401516-0DDE7D54-8A1D-455C-A5E5-8E87A738CE1E Q36419479-A88F0BE6-2530-441C-AD6F-85A4862E572C Q36486190-59DCFD97-09A7-4623-84FA-CD854EAE1C07 Q36551309-8FC571CC-A890-4784-A8F1-8D12D94A1855 Q36555263-737A9790-1383-4AE1-977E-F0B456C70315 Q36558909-9A3EFEF9-6B63-4D18-B78F-8659DC70BEF4 Q36611216-4B9626DA-4226-4004-919B-BC4D4A0699E3 Q36647012-10DCB00B-3302-4B2A-8BEC-5CA7EAA094BF

P2860

Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

http://www.wikidata.org/entity/Q33952538

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Viremia and drug resistance am ...... study in Soweto, South Africa.

@ast

Viremia and drug resistance am ...... study in Soweto, South Africa.

@en

type

label

Viremia and drug resistance am ...... study in Soweto, South Africa.

@ast

Viremia and drug resistance am ...... study in Soweto, South Africa.

@en

prefLabel

Viremia and drug resistance am ...... study in Soweto, South Africa.

@ast

Viremia and drug resistance am ...... study in Soweto, South Africa.

@en

P1433

Q33952538-4751325A-1949-403B-862F-91964B9944D2

P1476

Q33952538-337DFC35-B266-4092-8D9B-09ECC173612E

P2093

Q33952538-169C5BD7-87B0-4C32-B097-9F3399BA29CA

Q33952538-28C27048-D7BB-479A-8B28-D189FCBB57ED

Q33952538-2ECF16A6-13A2-47BE-8B01-68F4C78012A0

Q33952538-618A0AD2-58CB-43D1-B765-9B9D63BF23BC

Q33952538-6A4FBFE6-5D99-489D-951C-1F0D940781E9

Q33952538-CB377CB4-DE35-44BD-A2FD-79376460F116

Q33952538-E5935933-9A92-4748-A357-FD217B5B1463

P2860

Q33952538-0C1EBA42-6C66-49E5-9EE9-8DFD8FD8D9CE

Q33952538-0C68E16A-6946-4615-AE54-04A265729C44

Q33952538-122C1790-923A-4F27-8DBE-7FF67EE8B181

Q33952538-137A0A56-0E12-43FC-A2CC-EECB86A64B86

Q33952538-1A59869B-853B-45DE-BDE4-8CE5314AA1D0

Q33952538-1AEA7B07-143D-4164-82FB-E571F23FFD04

Q33952538-2161A651-3938-4D34-B287-AAB35DF455EA

Q33952538-23E00F9B-A02A-45F3-9436-523CA6C6E327

Q33952538-2ADFB0A6-A6F2-40BA-92F6-D3BBEDFFDC66

Q33952538-32369C78-BE26-44A0-B995-99071F94990D

P304

Q33952538-E2E2CA26-D596-430F-86C4-1EA3A786F8DF

P31

Q33952538-A1EA107E-B7F3-4375-9795-B048176B7394

P356

Q33952538-D92AC41A-E47E-455E-B516-E1B49E604C43

P407

Q33952538-A36835A2-AFEA-42DE-AD34-2E465CCCAFB0

P433

Q33952538-036D8244-FD10-41CF-B34A-C4E12CCAE976

P478

Q33952538-F9BEF564-79F7-4ADC-86ED-773FB048765F

P50

Q33952538-0A5B922D-681D-45F8-8391-3DF70508A965

Q33952538-99380CDE-9382-4251-8541-EC48B4F693C6

Q33952538-CE23081E-AC5E-4BC9-B8E6-D8678D8A4693

P577

Q33952538-E5520F48-1319-4A80-A7C1-9E01CAE47440

P5875

Q33952538-38F4E7B1-ED85-454D-AA25-4A317F1CD148

P698

Q33952538-4A99E16A-1F2A-4507-B9D0-AED7187748AC

P921

Q33952538-0EA83170-22D5-4E8D-9E46-0F092D52B9BC

Q33952538-758576B7-B87C-4A95-A9EE-B83D0981350B

P932

Q33952538-FE1191FA-6199-406B-AE7B-6D26247B63A1

P356

QAD.0B013E32833A097B

P1433

P1476

Viremia and drug resistance am ...... study in Soweto, South Africa.

@en

P2093

Alan Karstaedt

http://www.w3.org/2001/XMLSchema#string

Anna Mia Ekstrom

http://www.w3.org/2001/XMLSchema#string

David Katzenstein

http://www.w3.org/2001/XMLSchema#string

Fatima Laher

http://www.w3.org/2001/XMLSchema#string

Johanna Ledwaba

http://www.w3.org/2001/XMLSchema#string

Lerato Mohapi

http://www.w3.org/2001/XMLSchema#string

Max Petzold

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities

An automated genotyping system for analysis of HIV-1 and other microbial sequences.

HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?

Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review

Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.

Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.

The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.

Update of the drug resistance mutations in HIV-1: December 2009.

P304

1679-1687

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32833A097B

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Salome Charalambous

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44583674

http://www.w3.org/2001/XMLSchema#string

P698

20453629

http://www.w3.org/2001/XMLSchema#string

P921

Aafrikaa Kibbaa

antiretroviral drug

P932

2894994

http://www.w3.org/2001/XMLSchema#string